Antihyperglycemic and antihyperlipidemic action of Cinnamomi Cassiae (Cinnamon bark) extract in C57BL/Ks db/db mice

Archives of Pharmacal Research

Volumn 33, Issue 2, 2010, Pages 325-333

  Kim, Sung Hee ^a   Choung, Se Young ^a  

^a Kyung Hee University   (South Korea)

Author keywords

Adiponectin; Anti hyperglycemia; Anti hyperlipidemia; Cinnamomi Cassia; PPAR ; PPAR

Indexed keywords

ADIPONECTIN; CINNAMOMUM CASSIA EXTRACT; GLUCOSE; INSULIN; LIPID; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL MOUSE; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HYPERGLYCEMIA; HYPERLIPIDEMIA; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; LIPID METABOLISM; LIVER; MALE; MOUSE; NONHUMAN; POSTPRANDIAL STATE; PROTEIN EXPRESSION;

ABDOMINAL FAT; ADIPONECTIN; ANIMALS; ANTILIPEMIC AGENTS; BLOOD GLUCOSE; BODY WEIGHT; CHOLESTEROL; CINNAMATES; CINNAMOMUM; DIABETES MELLITUS, EXPERIMENTAL; HYPOGLYCEMIC AGENTS; INSULIN; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; PHYTOTHERAPY; PLANT BARK; PLANT EXTRACTS; PPAR ALPHA; PPAR GAMMA; TRIGLYCERIDES;

EID: 77949884990     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-010-0219-0     Document Type: Article

References (32)

1. C. J. Chou M. Haluzik C. Gregory K. R. Dietz C. Vinson O. Gavrilova M. L. Reitman 2002 WY14, 643, a peroxisome proliferator-activated receptor alpha (PPARalpha) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 mice J. Biol. Chem. 227 24484 24489 10.1074/jbc.M202449200
2. G. J. Etgen B. A. Oldham W. T. Johnson C. L. Broderick C. R. Montrose J. T. Brozinick E. A. Misener J. S. Bean W. R. Bensch D. A. Brooks A. J. Shuker C. J. Rito J. R. Mccarthy R. J. Ardecky J. S. Tyhonas S. L. Dana J. M. Bilakovics J. R. Patemiti K. M. Ogilivie S. Liu R. F. Kauffman 2002 A tailored therapy for the metabolic syndrome: the dual peroxisome proliferators - activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models Diabetes 51 1083 1087 10.2337/diabetes.51.4.1083 1:CAS:528:DC%2BD38Xis1Oju7o%3D 11916929
3. J. Folch M. Lees G. H. Sloane Stanley 1957 A simple method for the isolation and purification of total lipids from animal tissue J. Biol. Chem. 226 497 509 1:STN:280:DyaG2s%2FnsFCjtw%3D%3D 13428781
4. J. P. Frias J. G. Yu Y. T. Kruszynska J. M. Olefsky 2000 Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects Diabetes Care 23 64 69 10.2337/diacare.23.1.64 1:CAS:528: DC%2BD3cXnvVymtL4%3D 10857970
5. J. Fruebis T. S. Tsao S. Javorschi D. Ebbets-Reed M. R. Erickson F. T. Yen B. E. Bihain H. F. Lodish 2001 Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice Proc. Natl. Acad. Sci. U S A. 98 2005 2010 10.1073/pnas.041591798 1:CAS:528:DC%2BD3MXhsVWit78%3D 11172066 (Pubitemid 32165613)
6. W. W. Gesler 1992 Therapeutic landscapes: medical issues in light of the new cultural Geography Soc. Sci. Med. 34 735 746 10.1016/0277-9536(92)90360-3 1:STN:280:DyaK383psV2htQ%3D%3D 1376497
7. Q. Guo S. P. Sahoo P. R. Wang D. P. Milot M. C. Ippolito M. S. Wu J. Baffic C. Biswas M. Hernandez M. H. Lam N. Sharma W. Han L. J. Kelly K. L. MacNaul G. Zhou R. Desai J. V. Heck T. W. Doebber J. P. Berger D. E. Moller C. P. Sparrow Y. S. Chao S. D. Wright 2004 A Novel Peroxisome Proliferator- Activated Receptor α/γ Dual Agonist Demonstrates Favorable Effects on Lipid Homeostasis Endocrinology 145 1640 1648 10.1210/en.2003-1270 1:CAS:528:DC%2BD2cXis1Sju7s%3D 14701675 (Pubitemid 38402370)
8. P. Haban R. Simoncic E. Zidekova L. Ozdin 2002 Role of fasting serum C-peptide as a predictor of cardiovascular risk associated with the metabolic X-syndrome Med. Sci. Monit. 8 175 179
9. M. Herz D. Johns J. Reviriego L. D. Grossman C. Godin S. Duran F. Hawkins H. Lochnan F. Escobar-jimenez P. A. Hardin C. S. Konkoy M. H. Tan 2003 A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus Clin. Ther. 25 1074 1095 10.1016/S0149-2918(03)80068-1 1:CAS:528:DC%2BD3sXktVyisLk%3D 12809958 (Pubitemid 36532579)
10. W. A. Hsueh R. Law 2003 The central role of fat and effect of peroxisome proliferator activated receptor-gamma on progression of insulin resistance and cardiovascular disease Am. J. Cardiol. 92 3J 9J 10.1016/S0002-9149(03)00610-6 1:CAS:528:DC%2BD3sXnvVSht7s%3D 12957321
11. S. M. Jackson F. Parhami X. P. Xi J. A. Berliner W. A. Hsueh R. E. Law L. L. Demer 1999 Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction Arterioscler. Thromb. Vasc. Biol. 19 2094 2104 1:CAS:528:DyaK1MXmtFOrtrY%3D 10479650
12. S. Kersten J. Seydoux J. M. Peters F. J. Gonzalez B. Desvergne W. Wahli 1999 Peroxisome proliferatoractivated receptor alpha mediates the adaptive response to fasting J. Clin. Invest. 103 1489 1498 10.1172/JCI6223 1:CAS:528:DyaK1MXjvVSntLo%3D 10359558
13. H. Kim M. Haluzik Z. Asghar D. Yau J. W. Joseph A. M. Fernandez M. L. Reitman S. Yakar B. Stannard M. B. Heron-Milhavet D. Wheeler 2003 Peroxisome proliferator-activated receptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverse the lipotoxic state and improves glucose homeostasis Diabetes 52 1770 1778 10.2337/diabetes.52.7.1770 1:CAS:528:DC%2BD3sXltlWhtbg%3D 12829645
14. S. Kimura M. Tomita P. Froguel T. Kadowoki 2001 The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity Nat. Med. 7 941 946 10.1038/90984 11479627 (Pubitemid 32756432)
15. U. Kintscher R. E. Law 2005 PPARgamma-mediated insulin sensitization: the importance of fat versus muscle Am. J. Physiol. Endocrinol. Metab. 288 287 291 10.1152/ajpendo.00440.2004 (Pubitemid 40110633)
16. Y. Kitahara K. Miura K. Takesue T. Mine R. Wada Y. Uchida S. lto S. Yagihashi 2002 Decreased blood glucose excursion by nateglinide ameliorated neuropathic changes in Goto-Kakizaki rats, an animal model of nonobese type 2 diabetes Metabolism 51 1452 1457 10.1053/meta.2002.35195 1:CAS:528: DC%2BD38XosF2jtLs%3D 12404197
17. N. Kubota Y. Terauchi H. Miki H. Tamemoto T. Yamauchi K. Komeda S. Satoh R. Nakano C. Ishii T. Sugiyama K. Eto Y. Tsubamoto A. Okuno K. Murakami H. Sekihara G. Hasegawa M. Naito Y. Toyoshima S. Tanaka K. Shiota T. Kitamura T. Fujta O. Ezaki S. Aizawa T. Kadowaki 1999 PPARgamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance Mol. Cell 4 597 609 10.1016/S1097-2765(00)80210-5 1:CAS:528:DyaK1MXntFCgsLc%3D 10549291 (Pubitemid 29531139)
18. C. H. Lee P. Olson R. M. Evans 2003 Mini review: lipid metabolism, metabolic diseases, and peroxisome proliferators-activated receptors Endocrinology 144 2201 2207 10.1210/en.2003-0288 1:CAS:528:DC%2BD3sXktFehtL4%3D 12746275 (Pubitemid 36629867)
19. N. Maeda M. Takahashi T. Funahashi S. Kihara H. Nishizawa K. Kishida H. Nagaretani M. Matsuda R. Komuro N. Ouchi H. Kuriyama K. Hotta T. Nakamura I. Shimomura Y. Matsuzawa 2001 PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein Diabetes 50 2094 2099 10.2337/diabetes.50.9.2094 1:CAS:528:DC%2BD3MXmsFKns7k%3D 11522676
20. Y. Miyazaki A. Mahankli M. Matsuda L. Glass S. Mahankali E. Ferrannini K. Cusi L. J. Mandarino R. A. DeFronzo 2001 Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone Diabetes Care 24 710 719 10.2337/diacare.24.4.710 1:CAS:528:DC%2BD3MXivVOmur0%3D 11315836
21. J. J. Nolan B. Ludvik P. Beerdsen M. Joyce J. Olefsky 1994 Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone N. Engl. J. Med. 331 1188 1193 10.1056/NEJM199411033311803 1:STN:280:DyaK2M%2FitFGlsw%3D%3D 7935656 (Pubitemid 24331336)
22. P. Raskin E. B. Rappaport S. T. Cole Y. Yan R. Patwardhan M. I. Freed 2000 Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type diabetes Diabetologia 43 278 284 10.1007/s001250050045 1:CAS:528:DC%2BD3cXhsFyltbk%3D 10768088
23. J. K. Reddy T. Hashimoto 2001 Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system Annu. Rev. Nutr. 21 193 230 10.1146/annurev.nutr.21.1.193 1:CAS:528:DC%2BD3MXlvFyku78%3D 11375435 (Pubitemid 32695270)
24. A. S. Ryan D. M. Berman B. J. Nicklas M. Sinba R. L. Gingerich G. S. Meneilly J. M. Egan D. Elahi 2003 Plasma adiponectin and leptin levels, body composition, and glucose utilization in adult women with wide ranges of age and obesity Diabetes Care 26 2383 2388 10.2337/diacare.26.8.2383 1:CAS:528:DC%2BD3sXmslOkur4%3D 12882866 (Pubitemid 36993330)
25. K. Schoonjans M. Watanabe H. Suzuki A. Mahfoudi G. Krey W. Wahli P. Grimaldi B. Staels T. Yamamoto J. Auwerx 1995 Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferators response element in the C promoter J. Biol. Chem. 270 19269 19276 10.1074/jbc.270.33.19269 1:CAS:528:DyaK2MXnsFyhu7w%3D 7642600
26. K. A. Spratt 1998 A clinician's guide to a woman's heart J. Am. Osteopath. Assoc. 98 1 6
27. B. Staels J. Dallongeville J. Auwerx K. Schoonjans E. Leitersdorf J. C. Fruchart 1998 Mechanism of action of fibrates on lipid and lipoprotein metabolism Circulation 98 2088 2093 1:CAS:528:DyaK1cXnsFCisr8%3D 9808609
28. M. C. Sugden M. J. Holness 2004 Potential role of peroxisome proliferator-activated activated receptor-alpha in the modulation of glucose-stimulated insulin secretion Diabetes 53 S71 S81 10.2337/diabetes.53. 2007.S71 1:CAS:528:DC%2BD2cXhtlGqsbo%3D 14749269
29. P. Tontonoz E. Hu B. M. Spiegelman 1994 Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipidactivated transcription factor Cell 79 1147 1156 10.1016/0092-8674(94)90006-X 1:STN:280:DyaK2M%2FpsVaqsg%3D%3D 8001151
30. A. J. Vidal-Puig R. V. Considine M. Jimenez-Linan A. Werman W. J. Pories J. F. Caro J. S. Flier 1997 Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids J. Clin. Invest. 99 2416 2422 10.1172/JCI119424 1:CAS:528:DyaK2sXjsVGqtro%3D 9153284
31. T. Yamauchi J. Kamon H. Waki K. Murakami K. Motojima K. Komeda T. Ide N. Kubota Y. Terauchi K. Tobe H. Miki A. Tsuchida Y. Akanuma R. Nagai S. Kimura T. Kadowaki 2001 The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPAR gamma) deficiency and PPAR gamma agonist improve insulin resistance J. Biol. Chem. 276 41245 41254 10.1074/jbc.M103241200 1:CAS:528:DC%2BD3MXosVKgtrg%3D 11533050
32. W. S. Yang W. J. Lee T. Funahashi S. Tanaka Y. Matsuzawa C. L. Chao C. L. Chen T. Y. Tai L. M. Chuang 2001 Weight reducation increases plasma levels of an adiposederived anti-inflammatory protein, adiponectin J. Clin. Endocrinol. Metab. 86 3815 3819 10.1210/jc.86.8.3815 1:CAS:528:DC%2BD3MXlvFekurs%3D 11502817 (Pubitemid 32755982)